{
    "organizations": [],
    "uuid": "a4097c1e171ce1d08c71197afafff9fd0abad0ac",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-aemcolo-nda/brief-cosmo-pharmaceuticals-aemcolo-nda-accepted-by-fda-idUSASC0A32J",
    "ord_in_thread": 0,
    "title": "BRIEF-Cosmo Pharmaceuticals' Aemcolo NDA Accepted by FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Cosmo Pharmaceuticals NV:\n* FDA ACCEPTS NEW DRUG APPLICATION FOR AEMCOLO (RIFAMYCIN SV MMXÂ®) AND SETS PDUFA DATE FOR NOVEMBER 16, 2018\n* COSMO PHARMACEUTICALS NV - UPON FDA APPROVAL OF AEMCOLO, ARIES PHARMACEUTICALS TO LEAD U.S. COMMERCIAL EFFORTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-21T23:03:00.000+03:00",
    "crawled": "2018-05-22T02:24:51.019+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "cosmo",
        "pharmaceutical",
        "nv",
        "fda",
        "accepts",
        "new",
        "drug",
        "application",
        "aemcolo",
        "rifamycin",
        "sv",
        "set",
        "pdufa",
        "date",
        "november",
        "cosmo",
        "pharmaceutical",
        "nv",
        "upon",
        "fda",
        "approval",
        "aemcolo",
        "aries",
        "pharmaceutical",
        "lead",
        "commercial",
        "effort",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}